Sienna Biopharmaceuticals, a Westlake Village biotech company, announced positive results Friday for its topical pre-treatment to standard laser hair removal, referred to as SNA-001.
The recent trial involving 65 patients included men and women with white, gray, blonde, light red and light brown hair. Additional analysis showed that the treatment produced up to 31 percent reduction of light hair, according to a press release from Sienna.
“SNA-001 represents an exciting growth opportunity for the aesthetics market, and a potential solution for consumers with light hair who are well aware of the ineffectiveness of laser hair removal,” said Dr. Frederick Beddingfield III, chief executive of Sienna Biopharmaceuticals. “We are pleased with these results and will seek a strategic partner who can rapidly maximize the value of SNA-001.”
Although laser hair removal has been available for nearly 25 years, the treatment has been ineffective for people with light hair, limiting their options to temporary and sometimes costly treatments like waxing and razors. Laser hair removal procedures could increase by 27 percent in the United States, if people with light hair are now able to be treated, according to a study cited by the company.
Shares of Sienna Biopharmaceuticals (SNNA) closed Friday up 14 cents, or 5.2 percent, to $2.84 on the New York Stock Exchange.